{"created":"2021-03-01T06:31:18.305868+00:00","id":25792,"links":{},"metadata":{"_buckets":{"deposit":"57709b60-3293-4305-9491-351912a13984"},"_deposit":{"id":"25792","owners":[],"pid":{"revision_id":0,"type":"depid","value":"25792"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00025792","sets":["432:1291:1292:1318","453:456"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Clinical evaluation of EMDOGAIN(R) treatment in periodontal infrabony defects: 6-month results"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2000-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"22","bibliographicPageStart":"15","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"新潟歯学会雑誌"},{"bibliographic_title":"新潟歯学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"There is limited information available from clinical trials regarding the performance of enamel matrix derivative (EMD); EMDOGAIN(R) in the treatment of periodontal infrabony defects. This randomized, double-blind, placebo-controlled, split-mouth study was designed to compare the clinical and radiographical effects of EMD treatment to that of placebo-controlled treatment for infrabony defects. Sixteen patients were included in this clinical trial, each of whom had one or two pairs of infrabony defects located contralaterally in the same arch. Thirty-six infrabony defects were randomly assigned treatment with flap surgery plus EMD or flap surgery plus placebo. At baseline and at the 6 month follow-up evaluation visit, clinical and radiographic measurements were determined. Data were statistically analyzed using the Wilcoxon-signed ranks test (a=0.05). At the 6 month evaluation visit, bleeding on probing for the EMD group was less 0.11±0.32, compared to the placebo group, 0.72±0.46(P